Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan CD44-activated head and neck squamous cell carcinoma cells

MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyal...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 31; no. 2; pp. 149 - 160
Main Authors Bourguignon, L Y W, Earle, C, Wong, G, Spevak, C C, Krueger, K
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 12.01.2012
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog–Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of i nhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog–Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog–Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC.
AbstractList MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog–Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of i nhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog–Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog–Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC.
MicroRNAs are often associated with the pathogenesis of many cancers including Head and Neck Squamous Cell Carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to play a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog-Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation (ChIP) assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of inhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs (siRNAs) effectively blocks HA-mediated Nanog-Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression, but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 plays a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC.
MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog--Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of inhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog-Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/ Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC. Oncogene (2012) 31, 149-160; doi: 10.1038/onc.2011.222; published online 20 June 2011 Keywords: nanog; Stat-3; miR-21; hyaluronan; CD44; head & neck cancer
MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog--Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of inhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog-Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/ Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC.
Audience Academic
Author Krueger, K
Spevak, C C
Bourguignon, L Y W
Earle, C
Wong, G
Author_xml – sequence: 1
  givenname: L Y W
  surname: Bourguignon
  fullname: Bourguignon, L Y W
  email: lilly.bourguignon@ucsf.edu
  organization: San Francisco Veterans Affairs Medical Center and Department of Medicine, University of California at San Francisco & Endocrine Unit (111N2)
– sequence: 2
  givenname: C
  surname: Earle
  fullname: Earle, C
  organization: San Francisco Veterans Affairs Medical Center and Department of Medicine, University of California at San Francisco & Endocrine Unit (111N2)
– sequence: 3
  givenname: G
  surname: Wong
  fullname: Wong, G
  organization: San Francisco Veterans Affairs Medical Center and Department of Medicine, University of California at San Francisco & Endocrine Unit (111N2)
– sequence: 4
  givenname: C C
  surname: Spevak
  fullname: Spevak, C C
  organization: San Francisco Veterans Affairs Medical Center and Department of Medicine, University of California at San Francisco & Endocrine Unit (111N2)
– sequence: 5
  givenname: K
  surname: Krueger
  fullname: Krueger, K
  organization: San Francisco Veterans Affairs Medical Center and Department of Medicine, University of California at San Francisco & Endocrine Unit (111N2)
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21685938$$D View this record in MEDLINE/PubMed
BookMark eNp9ksluFDEQhlsoiCxw44wsOBAkevDSmy9Io2GVQpAInK2KXT3jpNue2N0ReSTeEvdMSAgC5INl-6vftfz72Y7zDrPsMaMzRkXzyjs945SxGef8XrbHirrKy1IWO9kelSXNJRd8N9uP8YxSWkvKH2S7nFVNKUWzl_04GbAnGruO9BDOMZDDY3B--YKAM-RkgCEXJNqlg866JVkH3_sBySerg_9yPM85I_h9HTBG690mRq-w9-nCxgGcRmIdWV1BNwbvwJHFm6LIQQ_2EgY0ZIVgNlEO9TmJFyP0fozbfDQEbZ3vYXOMD7P7LXQRH13vB9m3d2-_Lj7kR5_ff1zMj3JdCZmy1QCVaUqoi7YpUQhZU1mBAFqeUs0BdCna0tSnVUsFNVXZGEMNCsNMQVuU4iB7vdVdj6c9Go1uCNCpdbCpQVfKg1V3X5xdqaW_VILVsmE8CTy_Fgj-YsQ4qN7GqQRwmIpTklWsKGQtEnn4X5JR2jSiSHxCn_6BnvkxpKlMemVJKZdNgp5toSV0qKxrfUpQT5pqzuu6qdOvU4Gzv1BpGeytTuZqbbq_E_ByG5BmHmPA9qYZjKrJgyp5UE0eVMmDCX_yewNv4F-mS0C-BWJ6cksMt7X8Q5BseQfDGPB2FE5PzIT8BGLe89E
CODEN ONCNES
CitedBy_id crossref_primary_10_3390_ijms18091849
crossref_primary_10_1080_00016489_2017_1292049
crossref_primary_10_1007_s10637_016_0397_9
crossref_primary_10_1007_s13277_016_5294_5
crossref_primary_10_3748_wjg_v22_i26_5971
crossref_primary_10_3390_cancers15194898
crossref_primary_10_4161_sgtp_19110
crossref_primary_10_1155_2020_8573793
crossref_primary_10_23902_trkjnat_368829
crossref_primary_10_1038_s41598_017_11709_9
crossref_primary_10_1007_s00106_014_2931_4
crossref_primary_10_3390_cancers12020340
crossref_primary_10_3390_genes15050537
crossref_primary_10_1016_j_gene_2020_144936
crossref_primary_10_1038_onc_2013_173
crossref_primary_10_1053_j_gastro_2013_12_035
crossref_primary_10_1155_2015_186904
crossref_primary_10_1016_j_disamonth_2020_101034
crossref_primary_10_1007_s10620_012_2182_8
crossref_primary_10_1016_j_oraloncology_2020_104916
crossref_primary_10_1155_2016_7614971
crossref_primary_10_1038_srep07461
crossref_primary_10_1186_s12885_018_4631_z
crossref_primary_10_3892_or_2015_3710
crossref_primary_10_1038_bjc_2013_349
crossref_primary_10_1038_onc_2013_55
crossref_primary_10_1371_journal_pone_0087444
crossref_primary_10_1371_journal_pone_0093208
crossref_primary_10_3389_fonc_2020_589601
crossref_primary_10_18632_oncotarget_5290
crossref_primary_10_3389_fonc_2023_1247399
crossref_primary_10_3748_wjg_v20_i36_13071
crossref_primary_10_1007_s12035_012_8289_2
crossref_primary_10_1038_cddis_2017_248
crossref_primary_10_1371_journal_pone_0090615
crossref_primary_10_1016_j_oraloncology_2016_10_008
crossref_primary_10_1016_j_bioactmat_2024_05_011
crossref_primary_10_3390_ijms20051151
crossref_primary_10_3892_ijo_2013_1844
crossref_primary_10_1016_j_molonc_2014_05_012
crossref_primary_10_1371_journal_pone_0245871
crossref_primary_10_3389_fcell_2021_660210
crossref_primary_10_1016_j_canlet_2021_03_009
crossref_primary_10_3389_fonc_2019_00492
crossref_primary_10_3389_fonc_2022_909450
crossref_primary_10_1016_j_molmed_2013_10_005
crossref_primary_10_1038_onc_2012_638
crossref_primary_10_1016_j_ygyno_2014_02_033
crossref_primary_10_1007_s11033_019_05058_1
crossref_primary_10_1002_hed_24982
crossref_primary_10_3390_cancers13112759
crossref_primary_10_18632_oncotarget_11349
crossref_primary_10_1586_erm_12_134
crossref_primary_10_1038_srep10205
crossref_primary_10_3390_ijms23031275
crossref_primary_10_3389_fcell_2021_727640
crossref_primary_10_1158_0008_5472_CAN_15_1664
crossref_primary_10_18632_oncotarget_11464
crossref_primary_10_1155_2014_231418
crossref_primary_10_3390_ijms21238936
crossref_primary_10_3892_or_2014_3114
crossref_primary_10_1038_onc_2017_245
crossref_primary_10_1093_jrr_rrad043
crossref_primary_10_1038_s41467_017_01885_7
crossref_primary_10_1016_j_canlet_2012_06_013
crossref_primary_10_1038_s41467_023_35856_y
crossref_primary_10_1111_jpi_12940
crossref_primary_10_3390_cells9102200
crossref_primary_10_1016_j_ijcard_2015_05_020
crossref_primary_10_3390_ijms13089545
crossref_primary_10_3892_br_2014_306
crossref_primary_10_1053_j_seminoncol_2015_01_001
crossref_primary_10_1186_s13046_016_0359_2
crossref_primary_10_1095_biolreprod_114_120295
crossref_primary_10_1002_mco2_554
crossref_primary_10_1093_carcin_bgu024
crossref_primary_10_3892_ol_2016_5163
crossref_primary_10_1074_jbc_M111_308528
crossref_primary_10_1158_0008_5472_CAN_20_1079
crossref_primary_10_3233_CBM_201731
crossref_primary_10_3390_cancers11020177
crossref_primary_10_1158_1078_0432_CCR_18_0716
crossref_primary_10_3390_cimb44110360
crossref_primary_10_1002_jcp_30063
crossref_primary_10_1016_j_jconrel_2016_03_008
crossref_primary_10_1097_MD_0000000000002641
crossref_primary_10_4161_cc_23406
crossref_primary_10_1517_14728222_2016_1112791
crossref_primary_10_1016_j_canlet_2018_01_001
crossref_primary_10_1016_j_canlet_2013_02_042
crossref_primary_10_1111_iep_12079
crossref_primary_10_1016_j_oraloncology_2020_105002
crossref_primary_10_1177_1533034615599461
crossref_primary_10_1016_j_ejphar_2021_174147
crossref_primary_10_1002_ijc_28690
crossref_primary_10_1097_CAD_0000000000000783
crossref_primary_10_3390_cancers10120482
crossref_primary_10_1002_hed_25532
crossref_primary_10_1016_j_lfs_2020_118337
crossref_primary_10_1155_2015_989070
crossref_primary_10_1177_1010428317695920
crossref_primary_10_1517_14728222_2013_819853
crossref_primary_10_18632_oncotarget_13422
crossref_primary_10_1111_febs_16179
crossref_primary_10_1158_1078_0432_CCR_12_1436
crossref_primary_10_3892_ol_2013_1690
crossref_primary_10_1158_1078_0432_CCR_13_0595
crossref_primary_10_3389_fbioe_2022_794037
crossref_primary_10_1097_IGC_0000000000000861
crossref_primary_10_1016_j_oraloncology_2015_03_004
crossref_primary_10_3892_ol_2012_907
crossref_primary_10_1016_j_bmc_2024_117603
crossref_primary_10_1155_2020_8868849
crossref_primary_10_1080_01635581_2014_868912
crossref_primary_10_3390_ijms17040517
crossref_primary_10_3389_fgene_2022_864612
crossref_primary_10_3389_fimmu_2015_00235
crossref_primary_10_1002_ijc_31638
crossref_primary_10_1016_j_canlet_2015_11_003
crossref_primary_10_18632_aging_102505
crossref_primary_10_1016_j_ejca_2014_07_012
crossref_primary_10_1038_onc_2015_150
crossref_primary_10_3389_fcell_2018_00097
crossref_primary_10_4161_jkst_28055
crossref_primary_10_1002_jcb_30473
crossref_primary_10_3390_cancers13051021
crossref_primary_10_1016_j_ygyno_2014_01_034
crossref_primary_10_1155_2018_1823726
crossref_primary_10_1016_j_semcancer_2022_10_007
crossref_primary_10_23736_S2724_6329_23_04840_4
crossref_primary_10_3390_ijms20092304
crossref_primary_10_1002_stem_1161
crossref_primary_10_1002_lary_25834
crossref_primary_10_1158_1535_7163_MCT_16_0606
crossref_primary_10_3390_ijms242115812
crossref_primary_10_1016_j_jaut_2012_12_013
crossref_primary_10_1002_1878_0261_13551
crossref_primary_10_1016_j_ijporl_2018_06_043
crossref_primary_10_1096_fj_201900395RR
crossref_primary_10_18632_genesandcancer_54
crossref_primary_10_3390_cells8080840
crossref_primary_10_5966_sctm_2015_0048
crossref_primary_10_1097_MOO_0b013e32835e1d6e
crossref_primary_10_1158_0008_5472_CAN_14_1254
crossref_primary_10_1186_s12943_018_0833_x
crossref_primary_10_3892_br_2016_747
crossref_primary_10_1016_j_acuroe_2019_02_006
crossref_primary_10_1111_jop_12286
crossref_primary_10_1038_onc_2015_281
crossref_primary_10_3389_fonc_2020_01231
crossref_primary_10_1007_s40675_017_0062_7
crossref_primary_10_1111_jop_12449
crossref_primary_10_1016_j_reth_2021_01_004
crossref_primary_10_1002_biof_1813
crossref_primary_10_1007_s13277_016_4848_x
crossref_primary_10_1016_j_tibs_2019_06_007
crossref_primary_10_1007_s12015_016_9660_x
crossref_primary_10_3390_ijms24054704
crossref_primary_10_3390_pathogens11020266
crossref_primary_10_2217_epi_2021_0228
crossref_primary_10_1007_s00432_013_1494_1
crossref_primary_10_1080_15384047_2015_1121348
crossref_primary_10_1007_s00106_015_0111_9
crossref_primary_10_1007_s12015_018_9839_4
crossref_primary_10_1186_1476_4598_13_52
crossref_primary_10_1080_09513590_2020_1781080
crossref_primary_10_1158_1535_7163_MCT_17_0421
crossref_primary_10_18632_oncotarget_11138
crossref_primary_10_1002_bab_2150
crossref_primary_10_1038_onc_2016_404
crossref_primary_10_3390_ijms22020753
crossref_primary_10_1016_j_critrevonc_2013_07_012
crossref_primary_10_1074_jbc_M115_700021
crossref_primary_10_3390_ijms23158616
crossref_primary_10_1074_jbc_M114_603894
crossref_primary_10_1016_j_acuro_2018_08_003
crossref_primary_10_1016_j_gene_2022_146448
crossref_primary_10_1016_j_bbagen_2014_01_022
crossref_primary_10_1016_j_prp_2023_154949
crossref_primary_10_1093_bib_bbs082
crossref_primary_10_23736_S2724_6329_21_04637_4
crossref_primary_10_1002_stem_2007
Cites_doi 10.1042/bj20030407
10.1158/1078-0432.CCR-07-4404
10.1038/sj.onc.1210856
10.3322/CA.2007.0010
10.1074/jbc.M110.162305
10.1007/s10495-007-0087-3
10.3322/canjclin.55.2.74
10.1002/cncr.21432
10.1073/pnas.0510565103
10.1016/S0092-8674(03)00393-3
10.1074/jbc.R100039200
10.1126/science.277.5332.1630
10.1158/0008-5472.CAN-08-2655
10.1016/0092-8674(95)90311-9
10.1001/archoto.2010.25
10.1016/j.semcancer.2008.03.007
10.1038/nrc2889
10.1002/ijc.23831
10.1074/jbc.M109.027466
10.1158/1078-0432.CCR-06-2313
10.1182/blood-2007-03-081133
10.1016/j.ajpath.2010.11.077
10.1016/S0002-9440(10)64232-0
10.1074/jbc.R100038200
10.1002/lary.20506
10.1038/sj.onc.1203483
10.1074/jbc.M800109200
10.1074/jbc.M806708200
10.1089/scd.2009.0113
ContentType Journal Article
Copyright Macmillan Publishers Limited 2012
COPYRIGHT 2012 Nature Publishing Group
Copyright Nature Publishing Group Jan 12, 2012
Copyright_xml – notice: Macmillan Publishers Limited 2012
– notice: COPYRIGHT 2012 Nature Publishing Group
– notice: Copyright Nature Publishing Group Jan 12, 2012
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7TM
7TO
7U9
7X7
7XB
88A
88E
8AO
8C1
8FD
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9.
LK8
M0S
M1P
M2O
M7P
MBDVC
P64
PQEST
PQQKQ
PQUKI
Q9U
RC3
7T5
7X8
5PM
DOI 10.1038/onc.2011.222
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest_Research Library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
Genetics Abstracts
Immunology Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
Technology Research Database
ProQuest Central Essentials
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest Central (Alumni)
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList
Research Library Prep

Genetics Abstracts

MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
EISSN 1476-5594
EndPage 160
ExternalDocumentID 2558709601
A277874979
10_1038_onc_2011_222
21685938
onc2011222
Genre Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: R01 CA066163-16
– fundername: NCI NIH HHS
  grantid: R01 CA066163
– fundername: NIAMS NIH HHS
  grantid: P01 AR039448-19
– fundername: NIAMS NIH HHS
  grantid: P01 AR039448
– fundername: NCI NIH HHS
  grantid: R01 CA78633
– fundername: NCI NIH HHS
  grantid: R01 CA078633
– fundername: NCI NIH HHS
  grantid: R01 CA66163
– fundername: NIAMS NIH HHS
  grantid: P01AR39448
– fundername: NCI NIH HHS
  grantid: R01 CA078633-10
– fundername: NIAMS NIH HHS
  grantid: R01 AR050023
GroupedDBID -
-Q-
08R
0R
123
29N
2WC
39C
3O-
3V.
4.4
53G
55
5RE
70F
7X7
88A
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8R4
8R5
AADWK
AAPBV
AAWBL
AAYJO
AAZLF
ABAWZ
ABDBF
ABDEU
ABEFU
ABFLS
ABGIJ
ABPTK
ABUWG
ACGFS
ACKTT
ACPRK
ADBBV
ADBIT
ADHDB
ADQMX
AEDAW
AEJRE
AENEX
AEXYK
AFFNX
AFKRA
AFSHS
AGEZK
AHMBA
AHSBF
AJRNO
ALFFA
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B0M
BAWUL
BBAFP
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CAG
COF
CS3
DIK
DU5
DWQXO
E3Z
EAD
EAP
EBC
EBD
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMK
EPL
ESX
F5P
FDQFY
FEDTE
FERAY
FIZPM
FRP
FSGXE
FYUFA
GJ
GNUQQ
GUQSH
HCIFZ
HVGLF
HZ
IAO
IHR
INH
INR
ITC
JSO
KQ8
L7B
LK8
M0L
M1P
M2O
M7P
N9A
NAO
O9-
OK1
OVD
P2P
PADUT
PQEST
PQQKQ
PQUKI
PRINS
PROAC
PSQYO
Q-
Q2X
RIG
RNS
RNT
RNTTT
SNX
SNYQT
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TEORI
TR2
TSG
TUS
UDS
W2D
WH7
X7M
ZA5
ZXP
---
0R~
36B
406
AANZL
ABAKF
ABJNI
ABLJU
ABZZP
ACAOD
ACGFO
ACMJI
ACRQY
ACZOJ
ADFRT
AEMSY
AEVLU
AFBBN
AGHAI
AGQEE
AILAN
ALIPV
AMYLF
CCPQU
DNIVK
DPUIP
EMOBN
HMCUK
HZ~
IWAJR
JZLTJ
NQJWS
NXXTH
SOHCF
SRMVM
UKHRP
~8M
AAYZH
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
AATNV
AAYFA
ACBMV
ACBRV
ACBYP
ACIGE
ACTTH
ACVWB
ADMDM
ADYYL
AEFTE
AFNRJ
AGGBP
AJCLW
AJDOV
AMRJV
FIGPU
NYICJ
7TM
7TO
7U9
7XB
8FD
8FK
FR3
H94
K9.
MBDVC
P64
Q9U
RC3
7T5
7X8
5PM
ID FETCH-LOGICAL-c639t-3caa6d85a74f85e3397096a3a05b0c2aac53f5d7b6f030d658dd0de3d1d40fe93
IEDL.DBID 8C1
ISSN 0950-9232
IngestDate Tue Sep 17 21:01:25 EDT 2024
Fri Oct 25 22:20:54 EDT 2024
Fri Oct 25 09:23:18 EDT 2024
Wed Nov 06 02:53:20 EST 2024
Thu Feb 22 23:38:18 EST 2024
Tue Nov 12 22:52:11 EST 2024
Fri Sep 27 02:37:16 EDT 2024
Tue Oct 15 23:42:10 EDT 2024
Fri Oct 11 20:47:13 EDT 2024
Thu Oct 07 20:38:00 EDT 2021
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords nanog
Stat-3
miR-21
hyaluronan
CD44
head & neck cancer
Language English
License Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c639t-3caa6d85a74f85e3397096a3a05b0c2aac53f5d7b6f030d658dd0de3d1d40fe93
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC3179812
PMID 21685938
PQID 915500298
PQPubID 36330
PageCount 12
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3179812
proquest_miscellaneous_916144973
proquest_miscellaneous_1008834161
proquest_journals_915500298
gale_infotracmisc_A277874979
gale_infotracacademiconefile_A277874979
crossref_primary_10_1038_onc_2011_222
pubmed_primary_21685938
springer_journals_10_1038_onc_2011_222
nature_primary_onc2011222
ProviderPackageCode ABDEU
AEDAW
AAZLF
-Q-
AADWK
AAYJO
70F
ADQMX
EE.
RNTTT
SWTZT
ABGIJ
RNT
NAO
PublicationCentury 2000
PublicationDate 1-12-2012
PublicationDateYYYYMMDD 2012-01-12
PublicationDate_xml – month: 01
  year: 2012
  text: 1-12-2012
  day: 12
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
– name: New York
PublicationTitle Oncogene
PublicationTitleAbbrev Oncogene
PublicationTitleAlternate Oncogene
PublicationYear 2012
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Kashyap, V, Rezende, NC, Scotland, KB, Shaffer, SM, Persson, JL, Gudas, LJ 2009; 18
Nakamura, M, Nakatani, K, Uzawa, K, Ono, K, Uesugi, H, Ogawara, K 2005; 14
Bourguignon, LY 2008; 18
Bourguignon, LY, Spevak, CC, Wong, G, Xia, W, Gilad, E 2009a; 284
Wen, Z, Zhong, Z, Darnell, JE 1995; 82
Turley, EA, Noble, PW, Bourguignon, LY 2002; 277
Ezeh, UI, Turek, PJ, Reijo, RA, Clark, AT 2005; 104
Lu, J, Bai, L, Sun, H, Nikolovska-Coleska, Z, McEachern, D, Qiu, S 2008; 68
Volinia, S, Calin, GA, Liu, CG, Ambs, S, Cimmino, A, Petrocca, F 2006; 103
Wang, SJ, Wong, G, de Heer, AM, Xia, W, Bourguignon, LY 2009; 119
Darnell, JE 1997; 277
Gyrd-Hansen, M, Meier, P 2010; 10
Parkin, DM, Bray, F, Ferlay, J, Pisani, P 2005; 55
Huang, S 2007; 13
Löffler, D, Brocke-Heidrich, K, Pfeifer, G, Stocsits, C, Hackermüller, J, Kretzschmar, AK 2007; 110
Bourguignon, LY, Xia, W, Wong, G 2009b; 284
Hunter, AM 2007; 12
Song, JI, Grandis, JR 2000; 19
Toole, BP, Hascall, VC 2002; 161
Jemal, A, Siegel, R, Ward, E, Hao, Y, Xu, J, Murray, T 2008; 58
Chang, SS, Jiang, WW, Smith, I, Poeta, LM, Begum, S, Glazer, C 2008; 123
Asangani, IA, Rasheed, SAK, Nikolova, DA, Leupold, JH, Colburn, NH, Post, S 2008; 27
Bourguignon, LY, Peyrollier, K, Xia, W, Gilad, E 2008; 283
Toole, BP, Wight, TN, Tammi, MJ 2002; 277
Bourguignon, LY, Wong, G, Earle, C, Krueger, K, Spevak, CC 2010; 285
Mitsui, K, Tokuzawa, Y, Itoh, H, Segawa, K, Murakami, M, Takahashi, K 2003; 113
Chiou, SH, Yu, CC, Huang, CY, Lin, SC, Liu, CJ, Tsai, TH 2008; 14
Heinrich, PC, Behrmann, I, Haan, S, Hermanns, HM, Muller-Newen, G, Schaper, F 2003; 374
Torre, C, Wang, SJ, Xia, W, Bourguignon, LY 2010; 136
Wang, S, Bourguignon, LY 2011; 178
Darnell (CR9) 1997; 277
Mitsui, Tokuzawa, Itoh, Segawa, Murakami, Takahashi (CR19) 2003; 113
Heinrich, Behrmann, Haan, Hermanns, Muller-Newen, Schaper (CR12) 2003; 374
Huang (CR13) 2007; 13
Bourguignon, Xia, Wong (CR6) 2009; 284
Hunter (CR14) 2007; 12
Wen, Zhong, Darnell (CR30) 1995; 82
Bourguignon, Wong, Earle, Krueger, Spevak (CR5) 2010; 285
Torre, Wang, Xia, Bourguignon (CR25) 2010; 136
Gyrd-Hansen, Meier (CR11) 2010; 10
Chang, Jiang, Smith, Poeta, Begum, Glazer (CR7) 2008; 123
Song, Grandis (CR22) 2000; 19
Ezeh, Turek, Reijo, Clark (CR10) 2005; 104
Bourguignon, Spevak, Wong, Xia, Gilad (CR4) 2009; 284
Wang, Wong, de Heer, Xia, Bourguignon (CR29) 2009; 119
Nakamura, Nakatani, Uzawa, Ono, Uesugi, Ogawara (CR20) 2005; 14
Bourguignon, Peyrollier, Xia, Gilad (CR3) 2008; 283
Chiou, Yu, Huang, Lin, Liu, Tsai (CR8) 2008; 14
Parkin, Bray, Ferlay, Pisani (CR21) 2005; 55
Bourguignon (CR2) 2008; 18
Volinia, Calin, Liu, Ambs, Cimmino, Petrocca (CR27) 2006; 103
Jemal, Siegel, Ward, Hao, Xu, Murray (CR15) 2008; 58
Turley, Noble, Bourguignon (CR26) 2002; 277
Lu, Bai, Sun, Nikolovska-Coleska, McEachern, Qiu (CR18) 2008; 68
Wang, Bourguignon (CR28) 2011; 178
Löffler, Brocke-Heidrich, Pfeifer, Stocsits, Hackermüller, Kretzschmar (CR17) 2007; 110
Toole, Hascall (CR23) 2002; 161
Toole, Wight, Tammi (CR24) 2002; 277
Kashyap, Rezende, Scotland, Shaffer, Persson, Gudas (CR16) 2009; 18
Asangani, Rasheed, Nikolova, Leupold, Colburn, Post (CR1) 2008; 27
20479382 - Arch Otolaryngol Head Neck Surg. 2010 May;136(5):493-501
18441325 - J Biol Chem. 2008 Jun 20;283(25):17635-51
22714418 - Small GTPases. 2012 Jan-Mar;3(1):53-9
21356346 - Am J Pathol. 2011 Mar;178(3):956-63
18593985 - Clin Cancer Res. 2008 Jul 1;14(13):4085-95
19010913 - Cancer Res. 2008 Nov 15;68(22):9384-93
16211297 - Oncol Rep. 2005 Nov;14(5):1281-6
17968323 - Oncogene. 2008 Apr 3;27(15):2128-36
11717318 - J Biol Chem. 2002 Feb 15;277(7):4593-6
18798260 - Int J Cancer. 2008 Dec 15;123(12):2791-7
12787504 - Cell. 2003 May 30;113(5):631-42
12773095 - Biochem J. 2003 Aug 15;374(Pt 1):1-20
17332277 - Clin Cancer Res. 2007 Mar 1;13(5):1362-6
12213700 - Am J Pathol. 2002 Sep;161(3):745-7
18450475 - Semin Cancer Biol. 2008 Aug;18(4):251-9
11717317 - J Biol Chem. 2002 Feb 15;277(7):4589-92
19633292 - J Biol Chem. 2009 Sep 25;284(39):26533-46
19480567 - Stem Cells Dev. 2009 Sep;18(7):1093-108
7543024 - Cell. 1995 Jul 28;82(2):241-50
16228988 - Cancer. 2005 Nov 15;104(10):2255-65
15761078 - CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
20843787 - J Biol Chem. 2010 Nov 19;285(47):36721-35
19507218 - Laryngoscope. 2009 Aug;119(8):1518-30
17496199 - Blood. 2007 Aug 15;110(4):1330-3
17573556 - Apoptosis. 2007 Sep;12(9):1543-68
16461460 - Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
19047049 - J Biol Chem. 2009 Jan 30;284(5):2657-71
20651737 - Nat Rev Cancer. 2010 Aug;10(8):561-74
9287210 - Science. 1997 Sep 12;277(5332):1630-5
18287387 - CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
10851047 - Oncogene. 2000 May 15;19(21):2489-95
BP Toole (BFonc2011222_CR23) 2002; 161
Z Wen (BFonc2011222_CR30) 1995; 82
LY Bourguignon (BFonc2011222_CR5) 2010; 285
LY Bourguignon (BFonc2011222_CR4) 2009; 284
S Huang (BFonc2011222_CR13) 2007; 13
A Jemal (BFonc2011222_CR15) 2008; 58
BP Toole (BFonc2011222_CR24) 2002; 277
V Kashyap (BFonc2011222_CR16) 2009; 18
K Mitsui (BFonc2011222_CR19) 2003; 113
JE Darnell Jr (BFonc2011222_CR9) 1997; 277
LY Bourguignon (BFonc2011222_CR3) 2008; 283
S Volinia (BFonc2011222_CR27) 2006; 103
SS Chang (BFonc2011222_CR7) 2008; 123
UI Ezeh (BFonc2011222_CR10) 2005; 104
SJ Wang (BFonc2011222_CR29) 2009; 119
IA Asangani (BFonc2011222_CR1) 2008; 27
LY Bourguignon (BFonc2011222_CR6) 2009; 284
EA Turley (BFonc2011222_CR26) 2002; 277
S Wang (BFonc2011222_CR28) 2011; 178
M Nakamura (BFonc2011222_CR20) 2005; 14
D Löffler (BFonc2011222_CR17) 2007; 110
DM Parkin (BFonc2011222_CR21) 2005; 55
LY Bourguignon (BFonc2011222_CR2) 2008; 18
SH Chiou (BFonc2011222_CR8) 2008; 14
JI Song (BFonc2011222_CR22) 2000; 19
PC Heinrich (BFonc2011222_CR12) 2003; 374
AM Hunter (BFonc2011222_CR14) 2007; 12
J Lu (BFonc2011222_CR18) 2008; 68
M Gyrd-Hansen (BFonc2011222_CR11) 2010; 10
C Torre (BFonc2011222_CR25) 2010; 136
References_xml – volume: 13
  start-page: 1362
  year: 2007
  end-page: 1366
  article-title: Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications
  publication-title: Clin Cancer Res
  contributor:
    fullname: Huang, S
– volume: 123
  start-page: 2791
  year: 2008
  end-page: 2797
  article-title: MicroRNA alterations in head and neck squamous cell carcinoma
  publication-title: Int J Cancer
  contributor:
    fullname: Glazer, C
– volume: 103
  start-page: 2257
  year: 2006
  end-page: 2261
  article-title: A microRNA expression signature of human solid tumors defines cancer gene targets
  publication-title: Proc Natl Acad Sci USA
  contributor:
    fullname: Petrocca, F
– volume: 55
  start-page: 74
  year: 2005
  end-page: 108
  article-title: Global cancer statistics, 2002
  publication-title: CA Cancer J Clin
  contributor:
    fullname: Pisani, P
– volume: 19
  start-page: 2489
  year: 2000
  end-page: 2495
  article-title: STAT signaling in head and neck cancer
  publication-title: Oncogene
  contributor:
    fullname: Grandis, JR
– volume: 285
  start-page: 36721
  year: 2010
  end-page: 36735
  article-title: Hyaluronan-CD44 interaction promotes c-Src-mediated Twist signaling, microRNA-10b expression and RhoA RhoC upregulation leading to Rho-Kinase-associated cytoskeleton activation and breast tumor cell invasion
  publication-title: J Biol Chem
  contributor:
    fullname: Spevak, CC
– volume: 10
  start-page: 561
  year: 2010
  end-page: 574
  article-title: IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer
  publication-title: Nat Rev Cancer
  contributor:
    fullname: Meier, P
– volume: 14
  start-page: 1281
  year: 2005
  end-page: 1286
  article-title: Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R
  publication-title: Oncol Rep
  contributor:
    fullname: Ogawara, K
– volume: 12
  start-page: 1543
  year: 2007
  end-page: 1568
  article-title: The inhibitors of apoptosis (IAPs) as cancer targets
  publication-title: Apoptosis
  contributor:
    fullname: Hunter, AM
– volume: 161
  start-page: 745
  year: 2002
  end-page: 747
  article-title: Hyaluronan and tumor growth
  publication-title: Am J Pathol
  contributor:
    fullname: Hascall, VC
– volume: 14
  start-page: 4085
  year: 2008
  end-page: 4095
  article-title: Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma
  publication-title: Clin Cancer Res
  contributor:
    fullname: Tsai, TH
– volume: 283
  start-page: 17635
  year: 2008
  end-page: 17651
  article-title: Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells
  publication-title: J Biol Chem
  contributor:
    fullname: Gilad, E
– volume: 284
  start-page: 2657
  year: 2009b
  end-page: 2671
  article-title: Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells
  publication-title: J Biol Chem
  contributor:
    fullname: Wong, G
– volume: 374
  start-page: 1
  year: 2003
  end-page: 20
  article-title: Principles of interleukin (IL)-6-type cytokine signalling and its regulation
  publication-title: Biochem J
  contributor:
    fullname: Schaper, F
– volume: 284
  start-page: 26533
  year: 2009a
  end-page: 26546
  article-title: Hyaluronan-CD44 interaction with PKC promotes oncogenic signaling by the stem cell marker, Nanog and the production of microRNA-21 leading to downregulation of the tumor suppressor protein, PDCD4, anti-apoptosis and chemotherapy resistance in breast tumor cells
  publication-title: J Biol Chem
  contributor:
    fullname: Gilad, E
– volume: 104
  start-page: 2255
  year: 2005
  end-page: 2265
  article-title: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma
  publication-title: Cancer
  contributor:
    fullname: Clark, AT
– volume: 136
  start-page: 493
  year: 2010
  end-page: 501
  article-title: Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling
  publication-title: Arch Otolaryngol Head Neck Surg
  contributor:
    fullname: Bourguignon, LY
– volume: 178
  start-page: 956
  year: 2011
  end-page: 963
  article-title: Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance
  publication-title: Am J Pathol
  contributor:
    fullname: Bourguignon, LY
– volume: 27
  start-page: 2128
  year: 2008
  end-page: 2136
  article-title: Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer
  publication-title: Oncogene
  contributor:
    fullname: Post, S
– volume: 58
  start-page: 71
  year: 2008
  end-page: 96
  article-title: Cancer statistics, 2008
  publication-title: CA Cancer J Clin
  contributor:
    fullname: Murray, T
– volume: 18
  start-page: 1093
  year: 2009
  end-page: 1108
  article-title: Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs
  publication-title: Stem Cells Dev
  contributor:
    fullname: Gudas, LJ
– volume: 110
  start-page: 1330
  year: 2007
  end-page: 1333
  article-title: Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer
  publication-title: Blood
  contributor:
    fullname: Kretzschmar, AK
– volume: 82
  start-page: 241
  year: 1995
  end-page: 250
  article-title: Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation
  publication-title: Cell
  contributor:
    fullname: Darnell, JE
– volume: 119
  start-page: 1518
  year: 2009
  end-page: 1530
  article-title: CD44 variant isoforms in head and neck squamous cell carcinoma progression
  publication-title: Laryngoscope
  contributor:
    fullname: Bourguignon, LY
– volume: 68
  start-page: 9384
  year: 2008
  end-page: 9393
  article-title: SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1 2 and XIAP
  publication-title: Cancer Res
  contributor:
    fullname: Qiu, S
– volume: 113
  start-page: 631
  year: 2003
  end-page: 642
  article-title: The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells
  publication-title: Cell
  contributor:
    fullname: Takahashi, K
– volume: 18
  start-page: 251
  year: 2008
  end-page: 259
  article-title: Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression
  publication-title: Semin Cancer Biol
  contributor:
    fullname: Bourguignon, LY
– volume: 277
  start-page: 1630
  year: 1997
  end-page: 1635
  article-title: STATs and gene regulation
  publication-title: Science
  contributor:
    fullname: Darnell, JE
– volume: 277
  start-page: 4593
  year: 2002
  end-page: 4596
  article-title: Hyaluronan-cell interactions in cancer and vascular disease
  publication-title: J Biol Chem
  contributor:
    fullname: Tammi, MJ
– volume: 277
  start-page: 4589
  year: 2002
  end-page: 4592
  article-title: Signaling properties of hyaluronan receptors
  publication-title: J Biol Chem
  contributor:
    fullname: Bourguignon, LY
– volume: 374
  start-page: 1
  year: 2003
  end-page: 20
  ident: CR12
  article-title: Principles of interleukin (IL)-6-type cytokine signalling and its regulation
  publication-title: Biochem J
  doi: 10.1042/bj20030407
  contributor:
    fullname: Schaper
– volume: 14
  start-page: 4085
  year: 2008
  end-page: 4095
  ident: CR8
  article-title: Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-4404
  contributor:
    fullname: Tsai
– volume: 27
  start-page: 2128
  year: 2008
  end-page: 2136
  ident: CR1
  article-title: Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210856
  contributor:
    fullname: Post
– volume: 58
  start-page: 71
  year: 2008
  end-page: 96
  ident: CR15
  article-title: Cancer statistics, 2008
  publication-title: CA Cancer J Clin
  doi: 10.3322/CA.2007.0010
  contributor:
    fullname: Murray
– volume: 14
  start-page: 1281
  year: 2005
  end-page: 1286
  ident: CR20
  article-title: Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R
  publication-title: Oncol Rep
  contributor:
    fullname: Ogawara
– volume: 285
  start-page: 36721
  year: 2010
  end-page: 36735
  ident: CR5
  article-title: Hyaluronan-CD44 interaction promotes c-Src-mediated Twist signaling, microRNA-10b expression and RhoA/RhoC upregulation leading to Rho-Kinase-associated cytoskeleton activation and breast tumor cell invasion
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M110.162305
  contributor:
    fullname: Spevak
– volume: 12
  start-page: 1543
  year: 2007
  end-page: 1568
  ident: CR14
  article-title: The inhibitors of apoptosis (IAPs) as cancer targets
  publication-title: Apoptosis
  doi: 10.1007/s10495-007-0087-3
  contributor:
    fullname: Hunter
– volume: 55
  start-page: 74
  year: 2005
  end-page: 108
  ident: CR21
  article-title: Global cancer statistics, 2002
  publication-title: CA Cancer J Clin
  doi: 10.3322/canjclin.55.2.74
  contributor:
    fullname: Pisani
– volume: 104
  start-page: 2255
  year: 2005
  end-page: 2265
  ident: CR10
  article-title: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma
  publication-title: Cancer
  doi: 10.1002/cncr.21432
  contributor:
    fullname: Clark
– volume: 103
  start-page: 2257
  year: 2006
  end-page: 2261
  ident: CR27
  article-title: A microRNA expression signature of human solid tumors defines cancer gene targets
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0510565103
  contributor:
    fullname: Petrocca
– volume: 113
  start-page: 631
  year: 2003
  end-page: 642
  ident: CR19
  article-title: The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells
  publication-title: Cell
  doi: 10.1016/S0092-8674(03)00393-3
  contributor:
    fullname: Takahashi
– volume: 277
  start-page: 4593
  year: 2002
  end-page: 4596
  ident: CR24
  article-title: Hyaluronan-cell interactions in cancer and vascular disease
  publication-title: J Biol Chem
  doi: 10.1074/jbc.R100039200
  contributor:
    fullname: Tammi
– volume: 277
  start-page: 1630
  year: 1997
  end-page: 1635
  ident: CR9
  article-title: STATs and gene regulation
  publication-title: Science
  doi: 10.1126/science.277.5332.1630
  contributor:
    fullname: Darnell
– volume: 68
  start-page: 9384
  year: 2008
  end-page: 9393
  ident: CR18
  article-title: SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-2655
  contributor:
    fullname: Qiu
– volume: 82
  start-page: 241
  year: 1995
  end-page: 250
  ident: CR30
  article-title: Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation
  publication-title: Cell
  doi: 10.1016/0092-8674(95)90311-9
  contributor:
    fullname: Darnell
– volume: 136
  start-page: 493
  year: 2010
  end-page: 501
  ident: CR25
  article-title: Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling
  publication-title: Arch Otolaryngol Head Neck Surg
  doi: 10.1001/archoto.2010.25
  contributor:
    fullname: Bourguignon
– volume: 18
  start-page: 251
  year: 2008
  end-page: 259
  ident: CR2
  article-title: Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2008.03.007
  contributor:
    fullname: Bourguignon
– volume: 10
  start-page: 561
  year: 2010
  end-page: 574
  ident: CR11
  article-title: IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2889
  contributor:
    fullname: Meier
– volume: 123
  start-page: 2791
  year: 2008
  end-page: 2797
  ident: CR7
  article-title: MicroRNA alterations in head and neck squamous cell carcinoma
  publication-title: Int J Cancer
  doi: 10.1002/ijc.23831
  contributor:
    fullname: Glazer
– volume: 284
  start-page: 26533
  year: 2009
  end-page: 26546
  ident: CR4
  article-title: Hyaluronan-CD44 interaction with PKCɛ promotes oncogenic signaling by the stem cell marker, Nanog and the production of microRNA-21 leading to downregulation of the tumor suppressor protein, PDCD4, anti-apoptosis and chemotherapy resistance in breast tumor cells
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M109.027466
  contributor:
    fullname: Gilad
– volume: 13
  start-page: 1362
  year: 2007
  end-page: 1366
  ident: CR13
  article-title: Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-2313
  contributor:
    fullname: Huang
– volume: 110
  start-page: 1330
  year: 2007
  end-page: 1333
  ident: CR17
  article-title: Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer
  publication-title: Blood
  doi: 10.1182/blood-2007-03-081133
  contributor:
    fullname: Kretzschmar
– volume: 178
  start-page: 956
  year: 2011
  end-page: 963
  ident: CR28
  article-title: Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance
  publication-title: Am J Pathol
  doi: 10.1016/j.ajpath.2010.11.077
  contributor:
    fullname: Bourguignon
– volume: 161
  start-page: 745
  year: 2002
  end-page: 747
  ident: CR23
  article-title: Hyaluronan and tumor growth
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)64232-0
  contributor:
    fullname: Hascall
– volume: 277
  start-page: 4589
  year: 2002
  end-page: 4592
  ident: CR26
  article-title: Signaling properties of hyaluronan receptors
  publication-title: J Biol Chem
  doi: 10.1074/jbc.R100038200
  contributor:
    fullname: Bourguignon
– volume: 119
  start-page: 1518
  year: 2009
  end-page: 1530
  ident: CR29
  article-title: CD44 variant isoforms in head and neck squamous cell carcinoma progression
  publication-title: Laryngoscope
  doi: 10.1002/lary.20506
  contributor:
    fullname: Bourguignon
– volume: 19
  start-page: 2489
  year: 2000
  end-page: 2495
  ident: CR22
  article-title: STAT signaling in head and neck cancer
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1203483
  contributor:
    fullname: Grandis
– volume: 283
  start-page: 17635
  year: 2008
  end-page: 17651
  ident: CR3
  article-title: Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M800109200
  contributor:
    fullname: Gilad
– volume: 284
  start-page: 2657
  year: 2009
  end-page: 2671
  ident: CR6
  article-title: Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M806708200
  contributor:
    fullname: Wong
– volume: 18
  start-page: 1093
  year: 2009
  end-page: 1108
  ident: CR16
  article-title: Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs
  publication-title: Stem Cells Dev
  doi: 10.1089/scd.2009.0113
  contributor:
    fullname: Gudas
– volume: 103
  start-page: 2257
  year: 2006
  ident: BFonc2011222_CR27
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0510565103
  contributor:
    fullname: S Volinia
– volume: 27
  start-page: 2128
  year: 2008
  ident: BFonc2011222_CR1
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210856
  contributor:
    fullname: IA Asangani
– volume: 284
  start-page: 26533
  year: 2009
  ident: BFonc2011222_CR4
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M109.027466
  contributor:
    fullname: LY Bourguignon
– volume: 82
  start-page: 241
  year: 1995
  ident: BFonc2011222_CR30
  publication-title: Cell
  doi: 10.1016/0092-8674(95)90311-9
  contributor:
    fullname: Z Wen
– volume: 10
  start-page: 561
  year: 2010
  ident: BFonc2011222_CR11
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2889
  contributor:
    fullname: M Gyrd-Hansen
– volume: 55
  start-page: 74
  year: 2005
  ident: BFonc2011222_CR21
  publication-title: CA Cancer J Clin
  doi: 10.3322/canjclin.55.2.74
  contributor:
    fullname: DM Parkin
– volume: 136
  start-page: 493
  year: 2010
  ident: BFonc2011222_CR25
  publication-title: Arch Otolaryngol Head Neck Surg
  doi: 10.1001/archoto.2010.25
  contributor:
    fullname: C Torre
– volume: 178
  start-page: 956
  year: 2011
  ident: BFonc2011222_CR28
  publication-title: Am J Pathol
  doi: 10.1016/j.ajpath.2010.11.077
  contributor:
    fullname: S Wang
– volume: 119
  start-page: 1518
  year: 2009
  ident: BFonc2011222_CR29
  publication-title: Laryngoscope
  doi: 10.1002/lary.20506
  contributor:
    fullname: SJ Wang
– volume: 18
  start-page: 251
  year: 2008
  ident: BFonc2011222_CR2
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2008.03.007
  contributor:
    fullname: LY Bourguignon
– volume: 18
  start-page: 1093
  year: 2009
  ident: BFonc2011222_CR16
  publication-title: Stem Cells Dev
  doi: 10.1089/scd.2009.0113
  contributor:
    fullname: V Kashyap
– volume: 277
  start-page: 4593
  year: 2002
  ident: BFonc2011222_CR24
  publication-title: J Biol Chem
  doi: 10.1074/jbc.R100039200
  contributor:
    fullname: BP Toole
– volume: 285
  start-page: 36721
  year: 2010
  ident: BFonc2011222_CR5
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M110.162305
  contributor:
    fullname: LY Bourguignon
– volume: 58
  start-page: 71
  year: 2008
  ident: BFonc2011222_CR15
  publication-title: CA Cancer J Clin
  doi: 10.3322/CA.2007.0010
  contributor:
    fullname: A Jemal
– volume: 14
  start-page: 1281
  year: 2005
  ident: BFonc2011222_CR20
  publication-title: Oncol Rep
  contributor:
    fullname: M Nakamura
– volume: 104
  start-page: 2255
  year: 2005
  ident: BFonc2011222_CR10
  publication-title: Cancer
  doi: 10.1002/cncr.21432
  contributor:
    fullname: UI Ezeh
– volume: 13
  start-page: 1362
  year: 2007
  ident: BFonc2011222_CR13
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-2313
  contributor:
    fullname: S Huang
– volume: 113
  start-page: 631
  year: 2003
  ident: BFonc2011222_CR19
  publication-title: Cell
  doi: 10.1016/S0092-8674(03)00393-3
  contributor:
    fullname: K Mitsui
– volume: 161
  start-page: 745
  year: 2002
  ident: BFonc2011222_CR23
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)64232-0
  contributor:
    fullname: BP Toole
– volume: 110
  start-page: 1330
  year: 2007
  ident: BFonc2011222_CR17
  publication-title: Blood
  doi: 10.1182/blood-2007-03-081133
  contributor:
    fullname: D Löffler
– volume: 14
  start-page: 4085
  year: 2008
  ident: BFonc2011222_CR8
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-4404
  contributor:
    fullname: SH Chiou
– volume: 123
  start-page: 2791
  year: 2008
  ident: BFonc2011222_CR7
  publication-title: Int J Cancer
  doi: 10.1002/ijc.23831
  contributor:
    fullname: SS Chang
– volume: 68
  start-page: 9384
  year: 2008
  ident: BFonc2011222_CR18
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-2655
  contributor:
    fullname: J Lu
– volume: 284
  start-page: 2657
  year: 2009
  ident: BFonc2011222_CR6
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M806708200
  contributor:
    fullname: LY Bourguignon
– volume: 277
  start-page: 1630
  year: 1997
  ident: BFonc2011222_CR9
  publication-title: Science
  doi: 10.1126/science.277.5332.1630
  contributor:
    fullname: JE Darnell Jr
– volume: 12
  start-page: 1543
  year: 2007
  ident: BFonc2011222_CR14
  publication-title: Apoptosis
  doi: 10.1007/s10495-007-0087-3
  contributor:
    fullname: AM Hunter
– volume: 374
  start-page: 1
  year: 2003
  ident: BFonc2011222_CR12
  publication-title: Biochem J
  doi: 10.1042/bj20030407
  contributor:
    fullname: PC Heinrich
– volume: 19
  start-page: 2489
  year: 2000
  ident: BFonc2011222_CR22
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1203483
  contributor:
    fullname: JI Song
– volume: 283
  start-page: 17635
  year: 2008
  ident: BFonc2011222_CR3
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M800109200
  contributor:
    fullname: LY Bourguignon
– volume: 277
  start-page: 4589
  year: 2002
  ident: BFonc2011222_CR26
  publication-title: J Biol Chem
  doi: 10.1074/jbc.R100038200
  contributor:
    fullname: EA Turley
SSID ssj0007902
Score 2.5254774
Snippet MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21...
MicroRNAs are often associated with the pathogenesis of many cancers including Head and Neck Squamous Cell Carcinoma (HNSCC). In particular, microRNA-21...
SourceID pubmedcentral
proquest
gale
crossref
pubmed
springer
nature
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 149
SubjectTerms Apoptosis
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - metabolism
Carcinoma, Squamous Cell - pathology
CD44 antigen
Cell Biology
Cell Line, Tumor
Cell Nucleus - metabolism
Cell survival
Chemoresistance
Chemotherapy
Chromatin
Drug resistance
Drug Resistance, Neoplasm
Gene expression
Genetic aspects
Head & neck cancer
Head and neck cancer
Head and Neck Neoplasms - genetics
Head and Neck Neoplasms - metabolism
Head and Neck Neoplasms - pathology
Homeodomain Proteins - metabolism
Human Genetics
Humans
hyaluronan
Hyaluronan Receptors - metabolism
Hyaluronic Acid - metabolism
IAP protein
Immunoprecipitation
Internal Medicine
Medicine
Medicine & Public Health
MicroRNA
MicroRNAs - genetics
MicroRNAs - metabolism
miRNA
Nanog Homeobox Protein
Nuclear transport
Oncology
original-article
Physiological aspects
Promoter Regions, Genetic
Promoters
Signal Transduction
siRNA
squamous cell carcinoma
Stat3 protein
STAT3 Transcription Factor - metabolism
Stem cells
Transcription activation
Tumor cells
Tumor suppressor genes
Tumors
Tyrosine
Title Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan CD44-activated head and neck squamous cell carcinoma cells
URI http://dx.doi.org/10.1038/onc.2011.222
https://link.springer.com/article/10.1038/onc.2011.222
https://www.ncbi.nlm.nih.gov/pubmed/21685938
https://www.proquest.com/docview/915500298
https://search.proquest.com/docview/1008834161
https://search.proquest.com/docview/916144973
https://pubmed.ncbi.nlm.nih.gov/PMC3179812
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Zb9swDBbWFjtehi27vHaBBux8EGJbki0_DVnWohiQYOhWoG-GIslrsEVJcwDrT9q_HCk7CbzrMZBsMiZNfpI-k4S8GBcKgLJUTEplmdCpYFoIzmLjClOZmKvQpnM4yk7PxccLedFwc5YNrXITE0OgtjODe-Q9rGMe6oW_m18xbBqFh6tNB409cpBAmkNGnxrsGB55TTkEEBEzwDFpw3sH-b2ZN3X5zjRNWxmpicvtspot2Pkne_K3I9SQmU7ukbsNpKT92gfukxvOd8jNusnkdYfcHmx6unXIrWFzlP6A_Py8clOK-_Z0ihSdBX0DkXb29S3V3lLEoIxTZHdo_GCdzgNtz9EhEvjORn2WJtT9aFi0PlwD5kfW7hIRKbgSnXh6ea2_rxcA9n1v8EGAgUzopuYshRxgw1XemW90ebXWuAdR62Owv5GfTXX4uXxIzk-OvwxOWdO3gRnAO6Cd0TqzSupcVEo6DpAHFkqa61iOY5NqbSSvpM3HWQUhxoKnWBtbx21iRVy5gj8i-37m3RNC4T4chjNIsFK4LFOJEdYU0hkscjOuIvJyY7tyXpfnKMOxOlcl2LhEG5dg44i8RsOW-NaC0YxuPj4AKVj_quynOUQuUeRFRI5aM8FApjUc1a6xFQdiUEoQcrjxlrKJBMty67cReb4dxZsiuc07eLRYNlopjivNiNB_zAEUD0vfIucReVy731aBNMmwaB0IyFuOudNQT8r2iJ9chkriHMvVJaD4q40L7xT_22N8-t9_eEjuwERk-rAkPSL7q8XaPQPIthp3yV5-kXfD69klB--PR5_OfgFMMEIx
link.rule.ids 230,315,783,787,888,12068,12235,21400,27936,27937,31731,31732,33278,33279,33756,33757,43322,43591,43817,74073,74342,74630
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgESwXBOUVdgEj8TxYTWI7jxOqCqsC2x5gV-rNcm2HraButw-J_Un8S2actKvwOlaOM25mMv5sf_mGkOeTsgCgLAsmZWGZ0KlgWgjOYuNKU5mYF6FM53CUDU7Fx7EcN9ycVUOr3ObEkKjt3OAeeRd1zINe-NvFOcOiUXi42lTQuEquoQwXFjDIx7v1VpzXlEMAETEDHJM2vHew3517U8t3pmnampGavNyW1WzBzj_Zk78doYaZ6eg2udVAStqrY-AOueJ8h1yvi0xedMh-f1vTrUNuDJuj9Lvk55e1m1Hct6czpOgs6WvItPOvb6j2liIGZZwiu0PjB-t0EWh7jg6RwPd51GNpQt2PhkXrQx9wP7J2V4hIIZTo1NOzC_19swSw77v9dwIcZEI1NWcpzAE29PLOfKOr843GPYh6PAbrG_n5TIefq3vk9Oj9SX_AmroNzADegdEZrTNbSJ2LqpCOA-SBhZLmOpaT2KRaG8krafNJVkGKsRAp1sbWcZtYEVeu5PfJnp9795BQuA-H5gwmWClclhWJEdaU0hkUuZlUEXmx9Z1a1PIcKhyr80KBjxX6WIGPI_IKHavwrQWnGd18fABWUP9K9dIcMpco8zIih60rwUGm1RzVobEzB2bQSjBysI0W1WSCldrFbUSe7Vrxpkhu8w4eLcpGFwXHlWZE6D-uARQPS98y5xF5UIffbgBpkqFoHRjIW4F5OUI9Ve0WPz0LSuIc5eoSGPjLbQhfDvxvj_HRf__hU7I_OBkeq-MPo08H5CZ0QtYPS9JDsrdebtxjgG_ryZPwkv4CQ6ZCzw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Zj9MwELZgEQsvCMoVdgEjcT5YTeI4xxOqulTL0QoBK_XNcm2HraBut4fE_iT-JTOO21W4HivH8TQzGX-2v3xDyNNJVQJQFiUTojQsU2nGVJZxFmtb6VrHvPRlOoej_PgkezcW4yAptAq0ym1O9InazDXukXdRx9zrhXfrwIr4eDR4vThjWEAKD1pDNY3L5EoBixQM-WK8W3vFRUM_BEARM8A0aeDAgy3dudONlGeapq3ZKeTotsRmC4L-yaT87TjVz1KDm-RGgJe018TDLXLJug652hScPO-Qa_1tfbcO2R-GY_Xb5OfntZ1R3MOnM6TrLOlLyLrzr6-ocoYiHmWcItND4cfrdOEpfJYOkcz3adRjaULtj8Codb4PhAIyeFeITiGs6NTR03P1fbME4O-6_aMMnKV9ZTVrKMwHxvdyVn-jq7ONwv2Ixh6NtY7cfKb8z9UdcjJ486V_zEINB6YB-4B1WqnclEIVWV0KywH-wKJJcRWLSaxTpbTgtTDFJK8h3RiIGmNiY7lJTBbXtuJ3yZ6bO3ufULgPh-YcJluR2TwvE50ZXQmrUfBmUkfk2dZ3ctFIdUh_xM5LCT6W6GMJPo7IC3SsxDcYnKZV-BABRkEtLNlLC8hiWVVUETlsXQkO0q3mqAmN3XAwDI7iBznYRosMWWEldzEckSe7VrwpEt2chUeLEtJlyXHVGRH6j2sA0cMyuCp4RO414bczIE1yFLCDAYpWYF5YqKay3eKmp15VnKN0XQKGP9-G8IXhf3uMD_77Dx-TfXg_5Ye3o_cH5Dr0QQIQS9JDsrdebuxDQHLrySP_jv4CnXlHBw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Stem+cell+marker+%28Nanog%29+and+Stat-3+signaling+promote+MicroRNA-21+expression+and+chemoresistance+in+hyaluronan%2FCD44-activated+head+and+neck+squamous+cell+carcinoma+cells&rft.jtitle=Oncogene&rft.au=Bourguignon%2C+L+Y+W&rft.au=Earle%2C+C&rft.au=Wong%2C+G&rft.au=Spevak%2C+C+C&rft.date=2012-01-12&rft.issn=0950-9232&rft.volume=31&rft.issue=2&rft.spage=149&rft.epage=160&rft_id=info:doi/10.1038%2Fonc.2011.222&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9232&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9232&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9232&client=summon